|Day Low/High||26.55 / 27.64|
|52 Wk Low/High||18.70 / 29.77|
In trading on Monday, shares of Retrophin, Inc. crossed below their 200 day moving average of $22.55, changing hands as low as $22.50 per share.
Preliminary full-year 2017 revenue of approximately $155 million
Patient with PKAN showed persistent improvement in function over 30-month period of treatment with fosmetpantotenate
"Pharma bro" Martin Shkreli was found guilty on three of eight counts of securities fraud.
FORT Study to assess efficacy and safety of novel replacement therapy
Sarah Hassan, daughter of pharmaceutical executive Fred Hassan, was ignored by Shkreli for nearly a year before she received returns on her original investment.
More than 250 jurors have been interviewed, but there's still no luck in assembling a jury for the so-called 'Pharma Bro.'
The 'Pharma Bro's' lawyer attempts to bar the press again from 'Pharma Bro's' hearing.
Investors eyeing a purchase of Retrophin, Inc. stock, but cautious about paying the going market price of $19.48/share, might benefit from considering selling puts among the alternative strategies at their disposal.
One juror said Shkreli is 'the face of corporate greed in America.'
The trial for Martin Shkreli, the man alleged to have cheated investors and increasing a medication price by 5,000%, will begin today.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.